Egalet Hit With 2nd Investor Suit Over Abuse-Deterrent Label
Egalet Corp. investors filed a second securities class complaint Friday over the U.S. Food and Drug Administration's recent approval of an opioid painkiller, telling a Pennsylvania federal court that the company...To view the full article, register now.
Already a subscriber? Click here to view full article